BAKER BROS. ADVISORS LP
NEW YORK, NY · CIK 0001263508
Portfolio Value: $16.24B
Positions: 110
Period: 2020-03-31
Filed: 2020-05-15
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020Q2 2020Q1 2020Q4 2019Q3 2019Q2 2019Q1 2019Q4 2018Q3 2018Q2 2018Q1 2018Q4 2017Q3 2017Q2 2017Q1 2017Q4 2016Q3 2016Q2 2016Q1 2016Q4 2015Q3 2015Q2 2015Q1 2015Q4 2014
Portfolio Value
$16.24B
Positions
110
New
12
Increased
31
Decreased
18
Sold Out
190
BAKER BROS. ADVISORS LP Q1 2020 13F Filing Summary
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $16.24B across 110 positions in their Q1 2020 SEC 13F filing (period ending 2020-03-31). Top holdings include SE ($5.78B), INCY ($2.34B), ACAD ($1.77B). The top 10 positions account for 86.3% of the portfolio. This quarter saw 12 new positions, 31 increases, 18 reductions, 190 complete exits. Notable new buys: ALEC ($6.76M), THCH ($5.92M), THCH ($4.59M). Notable exits: Bellicum Pharmaceuticals, Inc., THCH, THCH.
All Holdings
Showing 1-50 of 110
Position Changes
| Stock | Value | Shares |
|---|---|---|
ALECAlector, Inc. | $6.76M | 280,000 |
THCHHorizon Therapeutics Public Ltd Co | $5.92M | 200,000 |
THCHArTara Therapeutics, Inc. | $4.59M | 199,671 |
PASGPassage Bio, Inc. | $4.33M | 275,000 |
IMNMImmunomedics, Inc. | $4.18M | 310,000 |
THCHKaruna Therapeutics, Inc. | $3.02M | 41,976 |
APLTApplied Therapeutics, Inc. | $2.15M | 65,934 |
DNLIDenali Therapeutics Inc. | $1.84M | 104,900 |
ARYA Sciences Acquisition Corp. | $1.53M | 150,000 |
Dicerna Pharmaceuticals, Inc. | $1.50M | 81,935 |
Bellicum Pharmaceuticals, Inc. | $1.17M | 249,123 |
GNFTYGenfit SA | $395.00K | 26,696 |